With the emergence and long-term Impact of COVID-19, Global Influenza Treatment Market to reach USD 6.41 billion by 2030
Bizwit Research & Consulting LLP’s recent analysis on the Global Influenza Treatment Market points towards a potential rise to USD 6.41 billion by 2030. Influenza treatment refers to the therapeutic interventions employed to alleviate the symptoms and complications associated with influenza, a highly contagious respiratory viral infection commonly known as the flu. The primary goals of influenza treatment are to reduce the severity and duration of symptoms, prevent complications, and limit the spread of the virus. The Influenza Treatment market is expanding because of factors such as increased prevalence of contagious respiratory illness, emerging prevalence of seasonal flu and rising drug approval activities.
Geographically, the global Influenza Treatment market has been segmented into North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa (MEA). North America dominated the market in 2022 owing to the dominance of key market players, rising disease prevalence, rising drug development activities in the region. Asia Pacific is expected to grow at a fastest rate during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for durg development, rising healthcare expenditure, and active participation of government and in the market space.
The global Influenza Treatment market is highly competitive owing to the presence of several key players such as NATCO Pharma Limited Novartis AG F. Hoffmann-La Roche Ltd BioCryst Pharmaceuticals, Inc. Sanofi GSK plc. Viatris Inc. (MYLAN) Teva Pharmaceutical Industries Ltd. Daiichi Sankyo Company, Limited. AstraZeneca, and others.
For further analysis on this or to request a sample copy of this report, please click the link mentioned below:
Key findings of the study suggest:
- Global Influenza Treatment Market is anticipated to grow with a healthy growth rate of more than 1.18% over the forecast period 2023-2030.
- In the Treatment segment, Oseltamivir Phosphate emerged out as the leading market segment in 2022.
- North America is anticipated to drive regional growth owing to rising drug development activities in the region.
- Asia Pacific is expected to grow at higher rate owing to rising target populations in the region
Bizwit Research & Consulting has considered following segments for the study:
By Treatment:
- Peramivir
- Zanamivir
- Baloxavir Marboxil
- Oseltamivir Phosphate
- Others
By Route of Administration:
- Oral
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Outlook
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Korea
- Australia
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
To get a sample of this report or to purchase a copy of the study, you can directly contact us at: sales@bizwitresearch.com
About Us
Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. The company has a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. Bizwit incorporate big data, expert analysis, and huge industry database to deliver client focused business consulting reports. Our analysts perform unbiased measurement and assessment of market opportunities to comprehend detailed market forecast. Our team of key opinion leaders evaluates the market size, growth prospects, end-use, applications, value & supply chain and top vendors in the industry to help the clients to take conversant business decisions without any vague assumptions.
Contact US
Global Business Development
Phone: +1 209 498-3066
Email: Sales@bizwitresearch.com
Website: www.bizwitresearch.com
